During the past decade, Toronto Memory Program conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 18 clinical trials were completed, i.e. on average, 56.3% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 16 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Toronto Memory Program" #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "Hoffmann-La Roche" with 6 trials sponsored, "AstraZeneca" with 3 trials sponsored, "Genentech, Inc." with 3 trials sponsored and "Pfizer" with 3 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Toronto Memory Program" #1 collaborator was "National Institute on Aging (NIA)" with 5 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Anavex Australia Pty Ltd." with 2 trials as a collaborator, "Anavex Germany GmbH" with 2 trials as a collaborator and "Biogen" with 2 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Toronto Memory Program" are "Alzheimer Disease" (17 trials), "Alzheimer's Disease" (16 trials), "Alzheimers Disease" (2 trials), "Early Alzheimer's Disease" (2 trials) and "Alzheimer Disease (AD)" (1 trials). Many other conditions were trialed in "Toronto Memory Program" in a lesser frequency.

Most popular intervention types in "Toronto Memory Program" are "Drug" (47 trials), "Other" (3 trials), "Biological" (2 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (26 trials), "Gantenerumab" (4 trials), "Lanabecestat" (3 trials), "Donanemab" (2 trials) and "Donepezil" (2 trials). Other intervention names were less common.

The vast majority of trials in "Toronto Memory Program" are 48 trials for "All" genders.

Currently, there are NaN active trials in "Toronto Memory Program". undefined are not yet recruiting, 4 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Toronto Memory Program, 1 suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Toronto Memory Program, 1 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".